PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,223,612 | -23.1% | 1,343,664 | +0.5% | 0.68% | -19.1% |
| Q2 2023 | $53,574,872 | +12.0% | 1,337,032 | +14.1% | 0.84% | +4.5% |
| Q1 2023 | $47,831,687 | +5.0% | 1,172,058 | +0.3% | 0.80% | -3.0% |
| Q4 2022 | $45,535,237 | -26.8% | 1,168,469 | -0.1% | 0.82% | -30.0% |
| Q3 2022 | $62,207,000 | -8.7% | 1,169,528 | +0.1% | 1.18% | -6.4% |
| Q2 2022 | $68,099,000 | -23.1% | 1,168,079 | +0.7% | 1.26% | -2.9% |
| Q1 2022 | $88,548,000 | +29.2% | 1,160,215 | +1.9% | 1.30% | +46.6% |
| Q4 2021 | $68,522,000 | +25.5% | 1,138,810 | +16.8% | 0.88% | +19.3% |
| Q3 2021 | $54,593,000 | -6.0% | 974,882 | +1.8% | 0.74% | -6.7% |
| Q2 2021 | $58,091,000 | -14.7% | 957,335 | -1.5% | 0.80% | -19.6% |
| Q1 2021 | $68,132,000 | +17.6% | 972,060 | +0.4% | 0.99% | +14.7% |
| Q4 2020 | $57,959,000 | -3.4% | 968,569 | -3.0% | 0.86% | -18.8% |
| Q3 2020 | $60,020,000 | +11.4% | 998,338 | -2.8% | 1.06% | +8.6% |
| Q2 2020 | $53,893,000 | +29.5% | 1,027,112 | -17.2% | 0.98% | -3.0% |
| Q1 2020 | $41,617,000 | -27.1% | 1,241,189 | -1.5% | 1.01% | -6.1% |
| Q4 2019 | $57,063,000 | +18.6% | 1,259,659 | -0.3% | 1.07% | +11.2% |
| Q3 2019 | $48,104,000 | -8.6% | 1,263,561 | +4.4% | 0.96% | -3.2% |
| Q2 2019 | $52,649,000 | +15.3% | 1,210,605 | +0.9% | 1.00% | +7.1% |
| Q1 2019 | $45,662,000 | -11.5% | 1,199,737 | +0.1% | 0.93% | -24.0% |
| Q4 2018 | $51,571,000 | -14.6% | 1,198,762 | -2.4% | 1.22% | +9.8% |
| Q3 2018 | $60,380,000 | +62.3% | 1,228,489 | +2.5% | 1.11% | +48.9% |
| Q2 2018 | $37,206,000 | +13.5% | 1,198,271 | +13.9% | 0.75% | +5.2% |
| Q1 2018 | $32,768,000 | -29.4% | 1,051,952 | +3.5% | 0.71% | -32.9% |
| Q4 2017 | $46,397,000 | +22.7% | 1,016,366 | +0.9% | 1.06% | +21.4% |
| Q3 2017 | $37,817,000 | -15.9% | 1,007,100 | +6.8% | 0.87% | -19.6% |
| Q2 2017 | $44,980,000 | +9.9% | 942,969 | +5.1% | 1.08% | +7.6% |
| Q1 2017 | $40,924,000 | +68.7% | 897,455 | +19.5% | 1.01% | +48.5% |
| Q4 2016 | $24,265,000 | +14.6% | 751,224 | +21.5% | 0.68% | +7.6% |
| Q3 2016 | $21,165,000 | +8.3% | 618,505 | +6.8% | 0.63% | -1.7% |
| Q2 2016 | $19,537,000 | -36.5% | 579,210 | -0.3% | 0.64% | -40.3% |
| Q1 2016 | $30,790,000 | -25.8% | 581,169 | +7.5% | 1.08% | -26.7% |
| Q4 2015 | $41,519,000 | +105.5% | 540,687 | +10.0% | 1.47% | +105.5% |
| Q3 2015 | $20,208,000 | -31.6% | 491,669 | +17.7% | 0.71% | -18.1% |
| Q2 2015 | $29,531,000 | -19.1% | 417,577 | +1.7% | 0.87% | -20.1% |
| Q1 2015 | $36,497,000 | -6.8% | 410,767 | -7.0% | 1.09% | -6.7% |
| Q4 2014 | $39,169,000 | -9.4% | 441,794 | -1.0% | 1.17% | -10.4% |
| Q3 2014 | $43,242,000 | +13.3% | 446,164 | +7.4% | 1.30% | +11.3% |
| Q2 2014 | $38,174,000 | +9.4% | 415,572 | -16.6% | 1.17% | +10.3% |
| Q1 2014 | $34,885,000 | +19.8% | 498,422 | -1.6% | 1.06% | +8.8% |
| Q4 2013 | $29,124,000 | -5.0% | 506,597 | -20.5% | 0.98% | -8.0% |
| Q3 2013 | $30,642,000 | +129.4% | 637,187 | +38.3% | 1.06% | +33.2% |
| Q2 2013 | $13,360,000 | – | 460,697 | – | 0.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |